Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

Supportive Care in Cancer

Volumn 23, Issue 3, 2015, Pages 723-732

  Raftopoulos, Harry ^a   Cooper, William ^b   O’Boyle, Erin ^c   Gabrail, Nashat ^d   Boccia, Ralph ^e   Gralla, Richard J ^f  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b TFS International   (United States)

^c FIBROGEN INC   (United States)

^d Gabrail Cancer Center   (United States)

^e Center for Cancer and Blood Disorders   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

APF530; Cancer; Chemotherapy induced nausea and vomiting (CINV); Extended release; Granisetron; Subcutaneous

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; GRANISETRON; IRINOTECAN; OXALIPLATIN; PALONOSETRON; TAXANE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TREATMENT RESPONSE; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; NEOPLASMS; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING;

EID: 84922268387     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2400-3     Document Type: Article

References (21)

1. NCCN Clinical Practice Guidelines in Oncology: Antiemesis—v1.2014. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
2. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 29:4189–4198
3. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232–v243
4. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109
5. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268
6. Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104–108
7. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294
8. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449
9. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482
10. Gralla R, Lichinitser M, Van DV, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577
11. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124
12. Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, Herrstedt J, Saito M, Tonato M (2011) Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 19(Suppl 1):S57–S62
13. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193–199
14. Rojas C, Raje M, Tsukamoto T, Slusher BS (2013) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37
15. Heller J, Barr J (2005) Biochronomer technology. Expert Opin Drug Deliv 2:169–183
16. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191–196
17. Hochberg J (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800–802
18. (2011) Kytril (granisetron hydrochloride) injection. Prescribing information. South San Francisco, CA: Genentech, Inc
19. (2010) Kytril (granisetron hydrochloride) tablets oral solution. Prescribing information. Roche Pharmaceuticals, Nutley, NJ
20. Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010) The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335:362–368
21. Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D (2013) Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 21:1453–1460